Bloodstream yeast infections: A 15-month survey

Epidemiology and Infection

Volumn 137, Issue 7, 2009, Pages 1037-1040

  Swinne, D ^a   Nolard, N ^a   Van Rooij, P ^a   Detandt, M ^a  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Antifungal susceptibilities; Bloodstream infections; Candidiasis

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

AGED; ANTIBIOTIC THERAPY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COMBINATION CHEMOTHERAPY; FEMALE; FUNGUS ISOLATION; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; INFECTION RISK; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MYCOSIS; SACCHAROMYCES CEREVISIAE; BELGIUM; FUNGEMIA; RISK FACTOR; YEAST;

ANTIFUNGAL AGENTS; BELGIUM; FUNGEMIA; HUMANS; RISK FACTORS; YEASTS;

EID: 67650469852     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268808001763     Document Type: Article

References (11)

1. Tortorano AM, et al. Candidaemia in Europe: Epidemiology and resistance. International Journal of Antimicrobial Agents 2006; 27: 359-366.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clinical Microbiology Reviews 2007; 20: 133-163.
3. Swinne D, et al. A one-year survey of candidemia in Belgium in 2002. Epidemiology and Infection 2004; 132: 1175-1180.
4. Barnett JA, Payne RW, Yarrow D. Yeasts: Characteristics and Identification, 3rd edn. Cambridge: Cambridge University Press, 2000, p. 1140.
5. Hennequin C, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. Journal of Clinical Microbiology 2001; 39: 551-559.
6. Clinical and Laboratory Standards Institute (CLSI). Quality control minimal inhibition concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints. Supplement M44-S1. Wayne, PA: CLSI, 2006.
7. Odds FC, Vranckx L, Woestenborghs F. Antifungal susceptibility testing of yeasts: Evaluation of technical variables for test automation. Antimicrobial Agents and Chemotherapy 1995; 39: 2051-2060.
8. Pfaller MA, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997-2000. Journal of Clinical Microbiology 2002; 40: 852-856.
9. Charlier C, et al. Fluconazole for the management of invasive candidiasis: Where do we stand after 15 years? Journal of Antimicrobial Chemotherapy 2006; 57: 384-410.
10. Lagrou K, et al. Fungemia at a tertiary care hospital: incidence, therapy, distribution and antifungal susceptibility of causative species. European Journal of Clinical Microbiology and Infectious Diseases 2007; 26: 541-547.
11. Swinne D, Watelle M, Nolard N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non-Candida albicans yeast isolates. Revista Iberoamericana de Micologia 2005; 22: 24-28.